Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and
notes several crucial activities carried out that should ignite a more significant sales
growth beyond 2022.
ANNONS
Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and
notes several crucial activities carried out that should ignite a more significant sales
growth beyond 2022.